Two Kinds of Radix Salviae Miltiorrhizae Injection for Angina Pectoris: A Systematic Review and Pharmacoeconomics Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 SHI Ya-fei ¹ ^# ,  YAN Hui ¹ ^# ,  SUN Shi-guang ¹ , WANG Rui ² , SUN Xiao-di ² , LI Yang ¹ , WANG Su-hui ²

1. Department of the Second Outpatient Services, The Military General Hospital of Beijing PLA, Beijing 100700, China;
2. Department of Pharmacy, The Military General Hospital of Beijing PLA, Beijing 100700, China;

Corresponding?author：

SUN Shi-guang, Email: ssgbzcg@163.com

Keywords：

Salvianolate; Danshen injection; Angina; Pharmacoeconomics; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20140050

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the effectiveness and safety of salvianolate injection and Danshen injection for patients with angina pectoris, and evaluate the cost of drug. Methods We electronically searched databases including PubMed, CENTRAL (Issue 4, 2013), CNKI, VIP and WanFang Data (2004.1 to 2013.5) for the randomized controlled trials (RCTs) on the comparison between salvianolate injection and Danshen injection for angina pectoris from January 2004 to May 2013. Relevant journals and conference proceedings were also manually retrieved. Two reviewers independently screened literature in accordance with the inclusion and exclusion criteria, extracted the data and assess the methodological quality of included studies. Then, meta-analysis was performed using RevMan 5.2 software. Results A total of 10 RCTs involving 1 196 patients were included. The results of meta-analysis showed that, salvianolate injection was obviously superior to Danshen injection in the effectiveness (OR=3.79, 95%CI 2.78 to 5.17, P < 0.000 01) and safety (OR=0.24, 95%CI 0.09 to 0.64, P=0.004), but lack of economic advantages in the treatment of the angina pectoris diseases. Conclusion Current evidence indicates that, salvianolate injection is a safe and effective scheme for angina pectoris, and Danshen injection is considered as a economic method. Because of the limited quantity and quality of currently-available research, the aforementioned conclusion should be verified by strictly-designed and large-scale sample RCTs.

Citation： SHI Ya-fei, YAN Hui, SUN Shi-guang, WANG Rui, SUN Xiao-di, LI Yang, WANG Su-hui. Two Kinds of Radix Salviae Miltiorrhizae Injection for Angina Pectoris: A Systematic Review and Pharmacoeconomics Analysis. Chinese Journal of Evidence-Based Medicine, 2014, 14(3): 287-291. doi: 10.7507/1672-2531.20140050 Copy

1.	?楊興華, 劉國安.中醫藥治療冠心病心絞痛的研究進展.中醫臨床研究, 2011, 3(20):120-122.
2.	趙瓊, 任大偉, 楊瑞花, 等.丹參不同產地加工方法對丹參多酚酸鹽質量的影響.中華中醫藥雜志, 2013, 28(3):645-648.
3.	虞敏, 張光輝.丹參注射液治療冠心病心絞痛的臨床觀察.海峽藥學, 2012, 24(6):126-127.
4.	國際心臟病學會和協會及世界衛生組織命名標準聯合專題組.缺血性心臟病的命名及診斷標準.中華心血管病雜志, 1981, 9(1):75.
5.	Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collbration, 2011. Available at:www.Cochrane-handbook.org.
6.	顏平, 羅心平, 施海明, 等.丹參多酚酸治療心絞痛患者的臨床療效及對血小板功能的影響.介入放射學雜志, 2004, 12(2):55-59.
7.	苗陽, 高鑄燁, 徐鳳芹, 等.丹參多酚酸鹽治療冠心病心絞痛(心血瘀阻證)的臨床觀察.中藥研究與信息, 2005, 7(10):23-26.
8.	鄭建文.注射用丹參多酚酸鹽治療冠心病45例.中西醫結合心腦血管病雜志, 2006, 4(12):1039-1040.
9.	李湘平, 尹桃.丹參多酚酸鹽注射液治療冠心病的療效觀察.中國現代醫學雜志, 2010, 20(4):619-621, 624.
10.	周菁, 羅海明, 姚春梅.丹參多酚酸鹽治療30例不穩定型心絞痛患者臨床療效觀察. 2011, (1):16-17.
11.	唐召力, 覃碧云, 滕秋葉, 等.丹參多酚酸鹽與丹參注射液對不穩定型心絞痛氧化修飾低密度脂蛋白、血友病因子和超敏C反應蛋白的作用比較.臨床薈萃, 2012, 27(17):1495-1497.
12.	趙業清.丹參多酚酸鹽注射液治療冠心病心絞痛65例臨床觀察.臨床合理用藥, 2012, 5(2B):70-71.
13.	王保成, 溫超英.丹參多酚酸鹽治療冠心病不穩定心絞痛臨床研究.中醫學報, 2009, 24(145):58-59.
14.	姜奧.注射用丹參多酚酸鹽治療冠心病心絞痛(心血疲阻型)的Ⅱ期臨床研究.成都中醫藥大學, 2005:4-01.
15.	金惠玲.注射用丹參多酚酸鹽治療穩定型心絞痛(心血癖阻型)的Ⅲ期臨床研究.成都中醫藥大學, 2006:4-01.
16.	劉麗娟, 錢莉玲.衛生經濟學評價及其在新生兒學科中的應用.中國循證兒科雜志, 2012(6):70-76.
17.	沈建通, 楊曉妍, 李幼平, 等.我國示范鄉鎮衛生院基本藥物循證評價與遴選之十一:冠心病.中國循證醫學雜志, 2012, 12(8):948-957.
18.	宋燕青, 徐向陽, 孫仁弟.注射用丹參多酚酸鹽的臨床應用概述.藥物流行病學雜志, 2012, 21(8):404-407.
19.	彭麗虹, 余正, 盛春雷.丹紅注射液治療冠心病心絞痛隨機對照試驗的系統評價.中國循證醫學雜志, 2011, 11(1):57-63.
20.	李然.中藥注射劑安全性"四性".中國醫院用藥評價與分析, 2012(5):92-95.

1. ?楊興華, 劉國安.中醫藥治療冠心病心絞痛的研究進展.中醫臨床研究, 2011, 3(20):120-122.
2. 趙瓊, 任大偉, 楊瑞花, 等.丹參不同產地加工方法對丹參多酚酸鹽質量的影響.中華中醫藥雜志, 2013, 28(3):645-648.
3. 虞敏, 張光輝.丹參注射液治療冠心病心絞痛的臨床觀察.海峽藥學, 2012, 24(6):126-127.
4. 國際心臟病學會和協會及世界衛生組織命名標準聯合專題組.缺血性心臟病的命名及診斷標準.中華心血管病雜志, 1981, 9(1):75.
5. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collbration, 2011. Available at:www.Cochrane-handbook.org.
6. 顏平, 羅心平, 施海明, 等.丹參多酚酸治療心絞痛患者的臨床療效及對血小板功能的影響.介入放射學雜志, 2004, 12(2):55-59.
7. 苗陽, 高鑄燁, 徐鳳芹, 等.丹參多酚酸鹽治療冠心病心絞痛(心血瘀阻證)的臨床觀察.中藥研究與信息, 2005, 7(10):23-26.
8. 鄭建文.注射用丹參多酚酸鹽治療冠心病45例.中西醫結合心腦血管病雜志, 2006, 4(12):1039-1040.
9. 李湘平, 尹桃.丹參多酚酸鹽注射液治療冠心病的療效觀察.中國現代醫學雜志, 2010, 20(4):619-621, 624.
10. 周菁, 羅海明, 姚春梅.丹參多酚酸鹽治療30例不穩定型心絞痛患者臨床療效觀察. 2011, (1):16-17.
11. 唐召力, 覃碧云, 滕秋葉, 等.丹參多酚酸鹽與丹參注射液對不穩定型心絞痛氧化修飾低密度脂蛋白、血友病因子和超敏C反應蛋白的作用比較.臨床薈萃, 2012, 27(17):1495-1497.
12. 趙業清.丹參多酚酸鹽注射液治療冠心病心絞痛65例臨床觀察.臨床合理用藥, 2012, 5(2B):70-71.
13. 王保成, 溫超英.丹參多酚酸鹽治療冠心病不穩定心絞痛臨床研究.中醫學報, 2009, 24(145):58-59.
14. 姜奧.注射用丹參多酚酸鹽治療冠心病心絞痛(心血疲阻型)的Ⅱ期臨床研究.成都中醫藥大學, 2005:4-01.
15. 金惠玲.注射用丹參多酚酸鹽治療穩定型心絞痛(心血癖阻型)的Ⅲ期臨床研究.成都中醫藥大學, 2006:4-01.
16. 劉麗娟, 錢莉玲.衛生經濟學評價及其在新生兒學科中的應用.中國循證兒科雜志, 2012(6):70-76.
17. 沈建通, 楊曉妍, 李幼平, 等.我國示范鄉鎮衛生院基本藥物循證評價與遴選之十一:冠心病.中國循證醫學雜志, 2012, 12(8):948-957.
18. 宋燕青, 徐向陽, 孫仁弟.注射用丹參多酚酸鹽的臨床應用概述.藥物流行病學雜志, 2012, 21(8):404-407.
19. 彭麗虹, 余正, 盛春雷.丹紅注射液治療冠心病心絞痛隨機對照試驗的系統評價.中國循證醫學雜志, 2011, 11(1):57-63.
20. 李然.中藥注射劑安全性"四性".中國醫院用藥評價與分析, 2012(5):92-95.

Chinese Journal of Evidence-Based Medicine

Two Kinds of Radix Salviae Miltiorrhizae Injection for Angina Pectoris: A Systematic Review and Pharmacoeconomics Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content